(Q35089942)

6 August 2017

1 reference

title

Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents (English)

1 reference

6 August 2017

Naidoo U

1

1 reference

6 August 2017

Goff DC

series ordinal

2

1 reference

6 August 2017

Klibanski A

series ordinal

3

1 reference

6 August 2017

publication date

1 April 2003

1 reference

6 August 2017

published in

Psychoneuroendocrinology

1 reference

6 August 2017

volume

28 Suppl 2

1 reference

6 August 2017

page(s)

97-108

1 reference

Osteoporosis and schizophrenia: can we limit known risk factors?

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Calcium Metabolism in Schizophrenic Patients on Long-Term Neuroleptic Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Osteoporosis as a Pediatric Problem

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Screening procedure for women at risk of developing postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Estimation of whole body bone resorption rate: A comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Osteoporosis in men with hyperprolactinemic hypogonadism

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Relation of Plasma Prolactin to Clinical Response in Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Prolactin Responses to Neuroleptics in Normal and Schizophrenic Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Decreased bone mineral density in medicated psychiatric patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Age and bone mass as predictors of fracture in a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Abnormal prolactin response to haloperidol challenge in men with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Prolactin levels and adverse events in patients treated with risperidone.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Decreased bone density in hyperprolactinemic women

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Neuroendocrine Tests during Treatment with Neuroleptic Drugs. I. Plasma Prolactin Response to Haloperidol Challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Vertebral body bone mineral content in hyperprolactinemic women

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Serum prolactin and clinical state during neuroleptic treatment and withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

The effect of sex steroids on the skeleton in premenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Urinary beta-1-galactosyl-0-hydroxylysine (GH) as a marker of collagen turnover of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Osteoporosis prevention, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Postabsorptive Urinary Hydroxyproline Test in Patients With Metastatic Bone Disease From Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Prolactin and antipsychotic medications: mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Hydroxyproline/creatinine ratios as estimates of bone resorption in early postmenopausal women. Fasting and 24-h urine samples compared.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Osteocalcin: diagnostic methods and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Clinical trials with melleril (TP21) in the treatment of schizophrenia. A two year study

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Clinical impact of hyperprolactinaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Osteoporosis: trials and tribulations

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

Urinary excretion levels of hydroxylysine glycosides in osteoporotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2802%2900129-4

7 January 2021

10.1016/S0306-4530(02)00129-4

Identifiers

DOI

1 reference

6 August 2017

1 reference